Results 41 to 50 of about 4,832 (178)

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

open access: yesAllergy, EarlyView.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier   +221 more
wiley   +1 more source

Supplementary Material for: Effect of benralizumab on mucus plugs in severe eosinophilic asthma

open access: yes, 2023
Introduction: Mucus plugs are associated with airway obstruction in severe asthma and are involved in the formation of activated eosinophils. Benralizumab, an anti-interleukin-5 receptor antibody, markedly reduces not only peripheral blood eosinophils ...
Sakai N. (4124452)   +11 more
core   +1 more source

Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.

open access: yes
BACKGROUND: Benralizumab is an eosinophil-depleting anti-interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.
Rothenberg, Marc E   +16 more
core   +3 more sources

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

open access: yesAllergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh   +7 more
wiley   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

open access: yesAllergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin   +4 more
wiley   +1 more source

Current Understanding of the Role of Eosinophils in CRSwNP and Implications for Treatment with Mepolizumab and Benralizumab

open access: yes, 2023
Background: International consensus statements now subdivide chronic rhinosinusitis (CRS) into several phenotypes and endotypes, including the presence of polyps (CRSwNP) and eosinophilia (eCRSwNP).
Carney, A Simon, Smith, Peter K
core   +1 more source

Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort

open access: yesJournal of Asthma and Allergy, 2018
Michel Aubier,1–4 Gabriel Thabut,1–3,5 Caroline Fabry-Vendrand6 1Inserm UMR1152, Physiopathology and Epidemiology of Respiratory Diseases, Paris, France; 2Faculty of Medicine, Paris Diderot University, Paris, France; 3Laboratory of Excellence,
Aubier M, Thabut G, Fabry-Vendrand C
doaj  

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis

open access: yesFrontiers in Allergy, 2022
BackgroundSevere eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation.
Maria D'Amato   +27 more
doaj   +1 more source

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

open access: yesAllergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy